<i>In Vitro</i> Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program
James A. Karlowsky, Meredith Hackel, Mark G. Wise, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Susan M. Cusick, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Abstract
Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales ( n = 13,731) and Pseudomonas aeruginosa ( n = 4,619) isolates cultured from infected patients attending hospitals in 56 countries.
Topics & Concepts
CefepimePseudomonas aeruginosaMicrobiologyBacilliAntimicrobialIn vitroGramGram-negative bacteriaBiologyMedicineBacteriaAntibiotic resistanceAntibioticsImipenemEscherichia coliGeneticsBiochemistryGeneAntibiotic Resistance in BacteriaAntibiotic Use and ResistancePneumonia and Respiratory Infections